Updated overall survival results from a randomized phase III trial comparing gefitinib with carboplatin–paclitaxel for chemo-naïve non-small cell lung cancer with sensitive EGFR gene mutations (NEJ002)

Details 詳細情報について

• CRID

  1360283692489015808

• DOI

  10.1093/annonc/mds214

• ISSN

  09237534

  http://id.crossref.org/issn/09237534

• Web Site

  https://api.elsevier.com/content/article/PII:S0923753419370279?httpAccept=text/xml

  https://api.elsevier.com/content/article/PII:S0923753419370279?httpAccept=text/plain

  http://academic.oup.com/annonc/article-pdf/24/1/54/13788762/mds214.pdf

• Data Source

  • Crossref
  • KAKEN